Two additional trials focused on HER2 + MBC with similar single-arm, open-label designs combining trastuzumab, cyclophosphamide, and an allogeneic GM-CSF-secreting breast tumor vaccine. The gene discussed is ERBB2; the disease is breast neoplasm.